NEW YORK, March 29 (Reuters) - Safety advantages of Abbott Laboratories' Xience stent over Boston Scientific Corp's rival Taxus stent increased between two and three years, according to long-term data ...
September 25, 2009 (San Francisco, California) — With results that back up those of SPIRIT IV, a second randomized controlled trial comparing the Xience V everolimus-eluting stent (Abbott) with a ...
Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at comparing the “late catch-up” phenomenon between the BuMA Supreme bioresorbable ...
Terumo's drug-eluting stent, Nobori, nabbed a bit of Abbott Laboratories' ($ABT) Xience glory as it proved in a large study to be just as effective as the top-selling ...
Abbott Laboratories (NYSE:ABT) is one of Goldman Sachs top healthcare stocks. On March 10, Abbott Laboratories (NYSE:ABT) confirmed the launch of its most advanced generation stent, XIENCE Skypoint, ...
Abbott, the global healthcare company, has launched XIENCE Skypoint in India. This is the company said is the most advanced generation stent within the globally trusted XIENCE family of everolimus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results